Sherbrooke Park Advisers LLC Cytek Biosciences, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $313 Billion
- Q4 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 41,774 shares of CTKB stock, worth $214,300. This represents 0.09% of its overall portfolio holdings.
Number of Shares
41,774
Previous 104,386
59.98%
Holding current value
$214,300
Previous $578 Million
53.12%
% of portfolio
0.09%
Previous 0.13%
Shares
5 transactions
Others Institutions Holding CTKB
# of Institutions
150Shares Held
74MCall Options Held
1KPut Options Held
0-
Black Rock Inc. New York, NY17.1MShares$87.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$60.1 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD8.25MShares$42.3 Million1.27% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$34.2 Million1.65% of portfolio
-
State Street Corp Boston, MA4.51MShares$23.1 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $691M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...